SCHEMBL2365722

SCHEMBL2365722

COC(=O)c1cccc(Nc2ccc(Cl)cn2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
ROCK1 Q13464 1/20 0.57
RAB9A P51151 7/20 0.56
NPC1 O15118 5/20 0.56
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
NPSR1 Q6W5P4 2/20 0.52
ATM Q13315 1/20 0.51
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
EGFR P00533 1/20 0.49
TNNI3K Q59H18 1/20 0.49
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
SRC P12931 1/20 0.49
RECQL P46063 1/20 0.49
GAA P10253 1/20 0.49
TSHR P16473 2/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365741 0.85 MEN1 (0.62) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL23455528 0.84 MAPT (0.67) MAPTROCK1RAB9AMEN1KMT2A
SCHEMBL13366028 0.84 MEN1 (0.62) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL29818053 0.82 MAPT (0.64) MAPTROCK1RAB9AMEN1KMT2A
SCHEMBL5928751 0.80 RAB9A (0.74) MAPTROCK1RAB9ANPC1MEN1
SCHEMBL23455564 0.80 ROCK1 (0.64) MAPTROCK1RAB9ANPC1MEN1
SCHEMBL27040080 0.79 MAPT (0.60) MAPTROCK1RAB9ANPC1MEN1
SCHEMBL29817888 0.79 MAPT (0.60) MAPTROCK1RAB9ANPC1MEN1
SCHEMBL691525 0.79 ROCK1 (0.57) MAPTROCK1RAB9ANPC1MEN1
SCHEMBL5928176 0.79 RAB9A (0.62) MAPTROCK1RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927549-B2 Adamantyl benzamide derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2015-01-06 US disclosed
US-20110224244-A1 Adamantyl Benzamide Derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2011-09-15 US disclosed
EP-2362730-A1 ADAMANTYL BENZAMIDE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2011-09-07 EP disclosed
WO-2010059618-A1 ADAMANTYL BENZAMIDE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224244-A1 Adamantyl Benzamide Derivatives HSD11B1, HSD17B11, HSD3B1 MAPT 4438/4885ROCK1 2148/4885RAB9A 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.